Yes. Dry eye symptoms become more common during and after menopause, and hormonal changes can affect tear production, meibomian gland function and the health of the ocular surface.
However, menopause related dry eye is not caused by the loss of one hormone alone. Estrogens, androgens and other hormones interact with the lacrimal glands, meibomian glands, eyelids, corneal nerves and immune system.
Age, medications, systemic health and environmental factors may also contribute. A comprehensive evaluation is therefore needed to determine what is affecting each patient.
Hormone receptors are present in several tissues involved in tear production and ocular surface health.
Hormonal changes may influence:
Changes in these functions can cause the tears to evaporate too quickly, become unstable or provide inadequate protection.
Symptoms may include:
These symptoms are not unique to menopause. The examination must determine whether meibomian gland dysfunction, aqueous tear deficiency, eyelid disease, inflammation or another condition is present.
Hormonal changes may influence the production and composition of meibomian gland oils. When the quantity or quality of these oils declines, the tear film may evaporate more rapidly.
Menopause can therefore be one contributor to MGD or hyperevaporative dry eye. Age related gland changes, rosacea, eyelid inflammation and incomplete blinking may be present at the same time.
Meibography is useful for determining whether the glands remain structurally intact or have developed shortening and dropout.
Yes. Some patients experience reduced aqueous tear production during or after menopause. When tear volume is inadequate, the eyes may feel dry, gritty or painful and the ocular surface may become damaged.
Aqueous deficiency can also be associated with medications or autoimmune conditions. Significant dry eye accompanied by dry mouth, joint symptoms, fatigue or other systemic concerns may warrant coordination with the patient’s primary care physician or rheumatologist.
Menopausal hormone therapy should not be started, stopped or changed solely to treat dry eye without guidance from the clinician managing the patient’s overall health.
Research on hormone therapy and dry eye has produced variable findings. The effect may depend on the hormones used, their formulation, the patient’s health and the mechanisms causing the ocular symptoms.
Dry eye treatment should be based on examination findings rather than assuming that hormone replacement will correct the tear-film problem.
At EnVision Dry Eye Center, an evaluation may include:
Testing helps determine whether symptoms are primarily related to excessive evaporation, inadequate tear production, inflammation, exposure or a combination of factors.
Treatment is directed at the identified mechanisms and may include:
Hormonal changes may be part of the history, but the treatment plan should address what is currently occurring in the tear film and ocular surface.
Dry eye symptoms during menopause are common, but they should not be dismissed as an unavoidable part of aging.
At EnVision Dry Eye Center, Dr. Jason Besecker evaluates the tear film, meibomian glands, eyelids and ocular surface to identify the factors contributing to each patient’s symptoms and develops a personalized treatment plan to address the underlying factors.
EnVision Dry Eye Center
3752 E Amity Avenue, Suite 103
Nampa, Idaho 83687
(208) 490-8823
Request a Comprehensive Dry-Eye Evaluation
Medically reviewed by Jason Besecker, OD, MS
Last updated: October 2026
Related question: What Causes Dry Eye?
Explore Dry Eye Questions & Answers